Glyburide

Cells were seeded into 12-well culture plates 16 h or 24 h before use in the experiments. For the priming of inflammasome activation, cells were treated with poly I:C (10 μg/mL, short synthetic analog of dsRNA; tlrl-picw, Invivogen), lipopolysaccharides (LPS, 10 ng/mL, L4130, Sigma-Aldrich Co., St. Louis, MO, USA), or flagellin (500 ng/mL, tlrl-stfla, Invivogen) for 16 h or 24 h as indicated in the figures. Before UV irradiation, media were changed to phosphate-buffered saline (PBS, 200 μL per well), after which the cells were exposed to UVA (365 nm) or UVB (312 nm) using the BIO-LINK crosslinker (BLX, Vilber Lourmat, Collégien, France). For UV-mediated inflammasome activation, macrophages (THP-1 cells or BMDMs) were exposed to 0.05 J/cm² UVB, while keratinocytes (HaCaT or HEK cells) were irradiated by 0.4 J/cm² UVB or 20 J/cm² UVA [15 (link)]. The cells were treated with RGE (1 mg/mL), NS (1 mg/mL), SF (0.5 mg/mL), glyburide (150 μM, Santa Cruz Biotechnology, Dallas, TX, USA), KCl (50 mM, Biosesang, Seoul, Republic of Korea), Z-VAD-FMK (10 μg/mL, R&D Systems, Minneapolis, MN, USA), diphenyleneiodonium (DPI, 100 μM, Tocris Bioscience, Bristol, UK), dimethyl sulfoxide (DMSO, 5%, Sigma-Aldrich Co.), BAPTA-AM (200 μM, Abcam, Cambridge, UK), MCC950 (200 nM, Invivogen), TAK-242 (TAK, 5 μM, Invivogen), or cycloheximide (50 μg/mL, Cayman, Ann Arbor, MI, USA).